Arcturus Therapeutics Receives U.S. FDA Fast Track Designation For ARCT-810, mRNA Therapeutic Candidate For Ornithine Transcarbamylase Deficiency
Portfolio Pulse from Happy Mohamed
Arcturus Therapeutics has received Fast Track Designation from the U.S. FDA for its mRNA therapeutic candidate ARCT-810, aimed at treating ornithine transcarbamylase (OTC) deficiency. The designation will facilitate development and expedite review of the therapy, potentially accelerating its approval.
June 01, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcturus Therapeutics' ARCT-810 receives FDA Fast Track Designation, potentially accelerating the approval process for the therapy.
The Fast Track Designation for ARCT-810 will facilitate development and expedite review of the therapy, which could lead to faster approval. This is positive news for Arcturus Therapeutics and could have a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100